Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sustained buying fuels indices
Fri, 22 Jul Closing

Indian stock markets began the day's proceedings on a firm note and maintained this buoyancy throughout the trading session today. Strong buying across index heavyweights fuelled the indices and ensured that they closed well above the dotted line. While the BSE-Sensex closed higher by around 286 points (up 1.5%), the NSE-Nifty closed higher by around 92 points (up 2%). The BSE Midcap and BSE Small cap also did well and notched gains of 1% each. Gains were largely seen in banking and auto stocks.

As regards global markets, Asian indices closed firm today while European indices have also opened in the green. The rupee was trading at Rs 44.36 to the dollar at the time of writing.

Barring Biocon, most pharma stocks such as Sun Pharma, Dr.Reddy's and Sun Pharma closed firm today. As per a leading business daily, Biocon's contract research subsidiary Syngene has entered into an agreement with US based Endo Pharmaceuticals to expand their collaboration to develop molecules to fight cancer. It must be noted that both the companies had tied up for drug discovery collaboration in March last year. As per the terms of the agreement signed last year, Endo would retain all rights to the molecules developed while Syngene would receive research fees, milestone payments and success fees from Endo. Syngene did well in 1QFY11 as its revenues grew by a robust 21% YoY led by expansion by existing clients, addition of new clients and evolution of the business mix towards higher value services. Thus, this deal bodes well for the company especially since the therapeutic field of oncology (anti-cancer) is one of the fastest growing classes in the global pharma market.

Hindustan Zinc announced its results for the quarter ended June 2011. The company's topline grew by 45% YoY and was driven both by volumes and realisations. However, the latter contributed more to the overall improvement. The company posted a 17% increase in refined zinc output, however the same for refined lead came in at 6% YoY. Production for silver also came in higher and stood at 8% YoY. However, the major contribution to topline growth came from higher realisations. Although commodity prices have softened in recent times, they are significantly higher on a YoY basis and this helped give revenues a big boost. With expenditure growing at a much slower rate of 32% YoY, the already high operating margins of the company received a further boost and increased 4% YoY to 55.9% in 1QFY12. PBT for the quarter came in higher by 70% YoY, an improvement over 56% YoY growth in operating profits, mainly on account of higher other income and better operating leverage. At 68% YoY, the net profit growth for the quarter has more or less come in line with the impressive PBT growth. The stock closed higher today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Sustained buying fuels indices". Click here!

1 Responses to "Sustained buying fuels indices"

Nikhil Shah

Jul 22, 2011

"Profit booking takes the toll" says the headline in Today's Market commentary section which is a repeat from yesterday (July 21st)!!!

Equitymaster requests your view! Post a comment on "Sustained buying fuels indices". Click here!

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Mar 16, 2018 (Close)